Targeting leukemia cells with specific RNA mutations
Official title: Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia
Funded at Fred Hutchinson Cancer Center · NIH-10891693 · Data updated 2026-11-12
This study is exploring new treatments for acute myeloid leukemia (AML) by using special tools that can target and kill cancer cells with certain mutations, while leaving healthy cells unharmed, and so far, early results look promising!
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $683,443 |
| NIH project number | 5R01CA283364-02 |
| Project ID | NIH-10891693 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have specific spliceosomal mutations.
✕Less likely to help
Patients without spliceosomal mutations or those with other types of leukemia may not benefit from this research.
What this research studies
This research focuses on developing new therapies for acute myeloid leukemia (AML) by targeting specific mutations in RNA splicing factors that are common in this disease. The approach involves creating synthetic introns that can selectively kill cancer cells with these mutations while sparing healthy cells. The research team combines expertise in cancer biology, RNA splicing, and drug delivery to design and test these innovative treatments. Preliminary results have shown promise in suppressing cancer growth in laboratory settings.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with AML and related blood disorders.
How similar studies have gone: Other research has shown success with similar targeted approaches in cancer treatment, indicating potential for this novel method.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Bradley, Robert K — Fred Hutchinson Cancer Center
- Study coordinator: Bradley, Robert K
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.